drugset
drugset / Trial / NCT04260802

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

NCT04260802 ↗

Phase 1/2 Terminated 73 enrolled Ocellaris Pharma, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types

Timeline

Start
2020-09-24
Primary completion
2025-11-07
Completion
2025-11-07

Drugs

EvaluationDrugModalityDoseRoute
Subject OC-001 Unknown — Intravenous
Background Avelumab Monoclonal antibody — Intravenous

Indications

cervical cancer cutaneous neuroendocrine carcinoma gastric cancer head and neck squamous cell carcinoma hepatocellular carcinoma metastatic malignant neoplasm non-small cell lung carcinoma ovarian cancer renal cell carcinoma sarcoma triple-negative breast carcinoma urinary bladder cancer urothelial carcinoma